Fabry disease: the main target organs in adults. Literature review


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Fabry disease (Anderson-Fabry disease) is an X-linked recessive lysosomal srorage disorder resulting from the inadequate activity of lysosomal hydrolase (alpha-galactosidase a), leading to progressive accumulation of globotriosylceramide (Gb3) in various cells, predominantly endothelial cells and smooth muscle cells of the vessels, with the damage of various organs. Fabry disease is manifested by progressive renal and heart failure, neuropathic pain, strokes, skin and gastrointestinal symptoms. Clinical manifestations begin in childhood, but in many patients it is diagnosed only in the adulthood. This review presents all the main aspects of the disease: epidemiology, pathophysiology, clinical manifestations in various systems, diagnosis, treatment, prevention, and impact on quality of life.

Full Text

Restricted Access

About the authors

K. V Firsov

SBHCI MR "Moscow Regional Scientific Research Clinical Institute n.a. M.F. Vladimirsky”

PhD in Medical Sciences, Neurologist Moscow, Russia

A. S Kotov

SBHCI MR "Moscow Regional Scientific Research Clinical Institute n.a. M.F. Vladimirsky”

Email: alex-013@yandex.ru
Doctor of Medical Sciences, Professor atthe Department of Neurology FAPE, Head of the Children’s Neurological Department for Section «Science» Moscow, Russia

References

  1. Hoffmann B., Mayatepek E. Fabry disease - aprovocation for pediatrics. Klin. Padiatr. 2006;218(1):38-40. German. PubMed PMID: 16432775.
  2. Hornbostel H., Scriba K Excision of skin in diagnosis of Fabry,s angiokeratoma with cardiovasorenal syndrome as phosphatide storage disease. Klin. Wochen. 1953;31:68-69.
  3. Sweeley C.C., Klionsky B. Fabry,s disease: classifications as a sphingolipidosis andpartial characterization of a novel glycolipid. J. Biol. Chem 1963;238:3148-3150.
  4. Fuller M., et al. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006.
  5. Germain D.P. Fabry disease. Orphanet. J. Rare Dis. 2010;5:30. doi: 10.1186/1750-1172-5-30.
  6. Ferraz M.J., Kallemeijn W. W., Mirzaian M., et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim. Biophys. Acta. 2014;1841(5):811-25. doi: 10.1016/j.bbalip.2013.11.004.
  7. Schiffmann R., Moore D.F. Neurological manifestations of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 22.
  8. Mauhin W., Lidove O., Masat E., et al. Innate and Adaptive Immune Response in Fabry Disease. JIMD. Rep. 2015;22:1-10. doi: 10.1007/8904_2014_371.
  9. Фирсов К.В., Котов А.С. Неврологические проявления при болезни Фабри. Журнал неврологии и психиатрии им. C.C. Корсакова. 2016;116(9):98-105. doi: 10.17116/jnevro 20161169198-105.
  10. Фирсов К.В., Котов А.С. Неврологические проявления болезни Фабри у детей и подростков. Русский журнал детской неврологии. 2017;12(3):51-doi: 10.17650/2073-8803-2017-12-3-51-57.
  11. Sawai S. Fabry Disease: Pathogenesis, Clinical Symptoms, and Treatment with Enzyme Replacement Therapy. Brain Nerve. 2015;67(9):1099-108. doi: 10.11477/mf.1416200266.
  12. Hopkin R.J., Jefferies J.L., Laney D.A., et al. Fabry Pediatric Expert Panel. The management and treatment of children with Fabry disease: A United States-based perspective. Mol. Genet. Metab. 2016;117(2):104-13. doi: 10.1016/j.ymgme.2015.10.007.
  13. Politei J., Thurberg B.L., Wallace E., et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin. Genet. 2016;89(1):5-9. doi: 10.1111/cge.12673.
  14. Buda P., Ksiqzyk J., Tylki-Szymanska A. Gastroenterological complications of Anderson-Fabry disease. Curr. Pharm. Des. 2013;19(33):6009-6013.
  15. Keshav S. Gastrointestinal manifestations of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 28.
  16. Keilmann A., Hegemann S., Conti G., et al. Fabry disease and the ear. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 25.
  17. Ries M., Kim H.J., Zalewski C.K., et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain. 2007;130(Pt. 1):143-150.
  18. Waldek S., Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC. Nephrol. 2014;15:72. doi: 10.1186/1471-2369-15-72.
  19. Basic-Jukic N., Kes P., Coric M., et al. Renal complications of Fabry disease. Curr. Pharm. Des. 2013;19(33):6046-6050.
  20. Mursã A., Ginghinã C., Jurcut R. Fabry disease - a primer for cardiologists. Rom. J. Intern. Med. 2014;52(4):216-222.
  21. Namdar M. Electrocardiographic Changes and Arrhythmia in Fabry Disease. Front Cardiovasc. Med. 2016;3:7. doi: 10.3389/fcvm.2016.00007.
  22. Pieruzzi F., Pieroni M., Zachara E., et al. Heart involvement in Anderson-Fabry disease: Italian recommendations for diagnostic follow-up and therapeutic management. G. Ital. Cardiol. (Rome). 2015;16(11):630-8. doi: 10.1714/2066.22434.
  23. Shi Q., Chen J., Pongmoragot J., et al. Prevalence of Fabry disease in stroke patients-- a systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 2014;23(5):985-92. doi: 10.1016/j.jstrokecerebrovasdis.2013.08.010.
  24. Kolodny E., Fellgiebel A., Hilz M.J., et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015;46(1):302-13. doi: 10.1161/STROKEAHA.114.006283.
  25. Moore D.F., Kaneski C.R., Askari H., et al. The cerebral vasculopathy of Fabry disease. J. Neurol. Sci. 2007;257(1-2):258-63.
  26. Muqtadar H., Testai F.D. Single gene disorders associated with stroke: a review and update on treatment options. Curr. Treat. Options Cardiovasc. Med. 2012;14(3):288-97. doi: 10.1007/s11936-012-0179-4.
  27. Germain D.P. Fabry disease. Orphanet. J. Rare Dis. 2010;5:30. doi: 10.1186/1750-1172-5-30.
  28. Ries M., Gupta S., Moore D.F., et al. Pediatric Fabry disease. Pediatrics. 2005;115(3):344-55. Epub 2005 Feb 15. PubMed PMID: 15713906.
  29. Desnick R.J., Brady R.O. Fabry disease in childhood. J Pediatr. 2004 May;144(5 Suppl):S20-6. Review. PubMed. PMID: 15126980.
  30. Hopkin R.J., Bissler J., Banikazemi M., et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr. Res. 2008;64(5):550-555. doi: 10.1203/PDR.0b013e318183f132. PubMed PMID: 18596579.
  31. Biegstraaten M., Linthorst G.E., van Schaik I.N., et al. Fabry disease: a rare cause of neuropathic pain. Curr. Pain Headache Rep. 2013;17(10):365. doi: 10.1007/s11916-013-0365-4.
  32. Bersano A., Lanfranconi S., Valcarenghi C., et al. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta. Neurol. Scand. 2012;126(2):77-97. doi: 10.1111/j.1600-0404.2012.01661.x.
  33. Bertelsen A.K., Tondel C., Krohn J., et al. Small fibre neuropathy in Fabry disease. J. Neurol. 2013;260(3):917-9. doi: 10.1007/s00415-012-6800-3.
  34. Dütsch M., Marthol H., Stemper B., et al. SmaUfiber dysfunction predominates in Fabry neuropathy. J. Clin. Neurophysiol. 2002;19(6):575-586.
  35. Üceyler N., Sommer C. Fabry disease: diagnosis and treatment. Schmerz. 2012;26(5):609-19. doi: 10.1007/s00482-012-1238-1.
  36. MacDermot J., MacDermot K.D. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur. J. Pharmacol. 2001;429(1-3):121- 125.
  37. Biegstraaten M., Binder A., Maag R., et al. The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur. J. Pain. 2011;15(8):822-829. doi: 10.1016/j.ejpain.2011.01.014.
  38. Biegstraaten M., Hollak C.E., Bakkers M., et al.Small fiber neuropathy in Fabry disease. Mol. Genet. Metab. 2012;106(2):135-41. Doi: 10.1016/j. ymgme.2012.03.010.
  39. Samuelsson K., Kostulas K., Vrethem M., et al. Idiopathic small fiber neuropathy: phenotype, etiologies, and the search for fabry disease. J. Clin. Neurol. 2014;10(2):108-18. doi: 10.3988/jcn.2014.10.2.108.
  40. Schiffmann R., Scott I.J. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr. 2002;91:48-52.
  41. Dütsch M., Hilz M.J. Neurological complications in Fabry disease. Rev. Med. Interne. 2010; 31(Suppl. 2):243-50. doi: 10.1016/S0248-8663(10)70021-7.
  42. Maag R., Binder A., Maier C., et al. Detection of a characteristic painful neuropathy in Fabry disease: a pilot study. Pain Med. 2008;9(8):1217-23. doi: 10.1111/j.1526-4637.2008.00470.x.
  43. Luciano C.A., Russell J.W., Banerjee T.K., et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve. 2002;26(5):622-629.
  44. Ghali J., Murugasu A., Day T., et al. Carpal tunnel syndrome in Fabry disease. JIMD. Rep. 2012;2:17-23. doi: 10.1007/8904_2011_37.
  45. Liguori R., Di Stasi V., Bugiardini E., et al. Small fiber neuropathy in female patients with fabry disease. Muscle Nerve. 2010;41(3):409-12. Doi: 10.1002/ mus.21606.
  46. Clavelou P., Besson G. Neurological aspects of Fabry disease. Presse Med. 2007;36(Spec. 1):1S65-1568.
  47. Domínguez R.O., Michref A., Tanus E., et al. Restless legs syndrome in Fabry disease: clinical feature associated to neuropathic pain is overlooked. Rev. Neurol. 2007;45(8):474-478.
  48. Sheth K.J., Bernhard G.C. The arthropathy of Fabry disease. Arthritis Rheum. 1979;22:781-783.
  49. Politei J., Remondino G., Heguilen R., et al. When arthralgia is not arthritis. Eur. J. Rheumatol. 2016;3(4):182-4. doi: 10.5152/eurjrheum.2016.15073. Epub 2016 Apr 5. PubMed PMID: 28149664; PubMed Central PMCID: PMC5283568.
  50. Namazova-Baranova L.S., Baranov A.A., Pushkov A.A., et al. Fabry disease in children: a federal screening programme in Russia. Eur. J. Pediatr. 2017 Sep doi: 10.1007/s00431-017-2992-y [Epub ahead of print] PubMed PMID: 28871487.
  51. Clavelou P., Besson G., Elziere C., et al. Neurological aspects of Fabry’s disease. Rev. Neurol (Paris). 2006;162(5):569-580.
  52. Tuttolomondo A., Pecoraro R., Simonetta I., et al. Neurological complications of Anderson-Fabry disease. Curr. Pharm. Des. 2013;19(33):6014-6030.
  53. Ginsberg L. Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 23.
  54. Cormican M.T., Paschalis T., Viers A., Alleyne C.H. Jr. Unusual case of subarachnoid haemorrhage in patient with Fabry’s disease: case report and literature review. BMJ. Case Rep. 2012;2012. pii: bcr0220125727. doi: 10.1136/bcr.02.2012.5727.
  55. Clavelou P., Besson G. Neurological aspects of Fabry disease. Presse Med. 2007;36(Spec. 1):1S65-1568.
  56. Löhle M., Hughes D., Milligan A., et al. Clinicalprodromes of neurodegeneration in Anderson-Fabry disease. Neurology. 2015 Apr 7;84(14):1454-64. doi: 10.1212/WNL.0000000000001450.
  57. Müller M.J. Neuropsychiatric and psychosocial aspects of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 29.
  58. Grewal R.P. Psychiatric disorders in patients with Fabry’s disease. Int. J Psychiatry Med. 1993;23(3):307-312.
  59. Müller M.J., Müller K.M., Dascalescu A., et al. Psychiatric and neuropsychological signs and symptoms in patients with fabry disease: literature review. Fortschr. Neurol. Psychiatr. 2005;73(11):687-693.
  60. Low M., Nicholls K., Tubridy N., et al. Neurology of Fabry disease. Intern. Med. J. 2007l;37(7):436-447.
  61. Bugescu N., Alioto A., Segal S., et al. The neurocognitive impact of Fabry disease on pediatric patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2015; 168B(3):204-10. doi: 10.1002/aamg.b.32297. Epub 2015 Mar 4. PubMed PMID: 25739920.
  62. Bugescu N., Naylor P.E., Hudson K., et al. The Psychosocial Impact of Fabry Disease on Pediatric Patients. J. Pediatr. Genet. 2016;5(3):141-9. doi: 10.1055/s-0036-1584357. Epub 2016 Jun 13. PubMed PMID: 27617155; PubMed Central PMCID: PMC4999331.
  63. Viana-Baptista M. Stroke and Fabry disease. J. Neurol. 2012;259(6):1019-28. doi: 10.1007/s00415-011-6278-4.
  64. Mendióroz M., Fernández-Cadenas I., Montaner J. Neurological manifestations of Fabry disease. Rev. Neurol. 2006;43(12):739-745.
  65. Fancellu L., Borsini W., Romani I., et al. Exploratory screening for Fabry’s disease in young adults with cerebrovascular disorders in northern Sardinia. BMC. Neurol. 2015;15:256. doi: 10.1186/s12883-015-0513-z. PubMed PMID: 26652600; PubMed Central PMCID: PMC4676830.
  66. Keshav S. Gastrointestinal manifestations of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 28. PubMed PMID: 21290669.
  67. Hopkin R.J., Bissler J., Banikazemi M., et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr. Res. 2008;64(5):550- 555. Doi: 101203/PDR.0b013e318183f132. PubMed PMID: 18596579.
  68. Buda P., Wieteska-Klimczak A., Ksiazyk J., et al. Diagnostic problems in a 17-year-old patient with gastrointestinal manifestations of Fabry disease. Med. Wieku. Rozwoj. 2011;15(1):69-72. Polish. PubMed PMID: 21786514.
  69. Politei J., Thurberg B.L., Wallace E., et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin. Genet. 2016;89(1):5-9. doi: 10.1111/cge.12673.
  70. Buda P., Ksiqzyk J., Tylki-Szymanska A. Gastroenterological complications of Anderson-Fabry disease. Curr. Pharm. Des. 2013;19(33):6009-6013.
  71. Keshav S. Gastrointestinal manifestations of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 28.
  72. Keilmann A., Hegemann S., Conti G., Haaioff D. Fabry disease and the ear. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 25.PubMed PMID: 21290702.
  73. Keilmann A. Inner ear function in children with Fabry disease. Acta. Paediatr. Suppl. 2003;92(443):31-32; discussion 27. PubMed PMID: 14989463.
  74. Keilmann A., Hajioff D., Ramaswami U; FOS Investigators. Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J. Inherit. Metab. Dis. 2009;32(6):739- 744. doi: 10.1007/s10545-009-1290-x. Epub 2009 Oct 27. PubMed PMID: 19876760.
  75. Allen L.E., Cosgrave E.M., Kersey J.P., Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br. J. Ophthalmol. 2010;94(12):1602-1605. Doi: 10.1136/ bao.2009.176651. Epub 2010 Jun 24. PubMe. PMID: 20576773.
  76. Abe H., Sakai T., Sawaguchi S., et al. Ischemic optic neuropathy in a female carrier with Fabry’s disease. Ophthalmol. 1992;205(2):83-88.
  77. Pitz S., Grube-Einwald K., Renieri G., Reinke J. Subclinical optic neuropathy in Fabry disease. Ophthalmic. Genet. 2009;30(4):165-171. doi: 10.3109/13816810903148004.
  78. Kumagai K., Mitamura Y., Mizunoya S., et al. A case of anterior ischemic optic neuropathy associated with Fabry’s disease. Jpn. J. Ophthalmol. 2008;52(5):421-423. doi: 10.1007/s10384-008-0572-4.
  79. Sivley M.D. Fabry disease: a review of ophthalmic and systemic manifestations. Optom. Vis. Sci. 2013;90(2):e63-78. doi: 10.1097/OPX.0b013e31827ec7eb.
  80. Sodi A., Ioannidis A., Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 26.
  81. Kalkum G., Pitz S., Karabul N., et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC. Ophthalmol. 2016;16(1):202. PubMed PMID: 27852300; PubMed Central PMCID: PMC5112699.
  82. Giuseppe P., Daniele R., Rita B.M. Cutaneous complications of Anderson-Fabry disease. Curr. Pharm. Des. 2013;19(33):6031-6036.
  83. Lidove O., Jaussaud R., Aractingi S. Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 24.
  84. Basic-Jukic N., Kes P., Coric M., Basic-Kes V. Renal complications of Fabry disease. Curr. Pharm. Des. 2013;19(33):6046-6050. Review. PubMed PMID: 23448456.
  85. Tondel C., Bostad L., Hirth A., Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am. J. Kidney Dis. 2008;51(5):767-776. doi: 10.1053/j.ajkd.2007.12.032. Epub 2008 Mar
  86. Erratum in: Am. J. Kidney Dis. 2009 Mar;53(3):567. PubMed PMID: 18436087.
  87. Tondel C., Bostad L., Laegreid L.M., et al. Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. Clin. Ther. 2008;30(Suppl. B):42. PubMed PMID: 18395135.
  88. Wijburg F.A., Bénichou B., Bichet D.G., et al. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One. 2015;10(5):e0124987. Doi: 10.1371/ journal.pone.0124987. ECollection 2015. PubMed PMID: 25955246; PubMed Central PMCID: PMC4425695.
  89. Tondel C., Kanai T., Larsen K.K., et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129(1):16-21. doi: 10.1159/000369309. Epub 2014 Dec 17. PubMed PMID: 25531941.
  90. Cybulla M., Kurschat C., West M., et al.Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J. Nephrol. 2013;26(4):645-651. doi: 10.5301/jn.5000214. Epub 2012 Sep 19. Review. PubMed PMID: 23023720.
  91. Manwaring V., Heywood W.E., Clayton R., et al. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients. J. Proteome. Res.2013;12(5):2013-2021. doi: 10.1021/pr301200e. Epub 2013 Apr 2. PubMed PMID: 23464927.
  92. Auray-Blais C., Ntwari A., Clarke J.T., et al. How well does urinary Lyso-Gb3 function as a biomarker in Fabry disease? Clin. Chim. Acta. 2010;411(23-24):1906-1914. doi: 10.1016/j.cca.2010.07.038. Epub 2010 Aug 14. PubMed PMID: 20716442.
  93. Auray-Blais C., Cyr D., Ntwari A., et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab. 2008;93(3):331-340. Epub 2007 Nov 26. PubMed PMID: 18023222.
  94. Najafian B., Mauer M., Hopkin R.J., Svarstad E. Renal complications of Fabry disease in children. Pediatr. Nephrol. 2013;28(5):679-687. doi: 10.1007/s00467-012-2222-9. Epub 2012 Aug 17. Review. PubMed PMID: 22898981; PubMed Central PMCID: PMC3811930.
  95. Ramaswami U., Najafian B., Schieppati A., et al. Assessment of renal pathology and dysfunction in children with Fabry disease. Clin. J. Am. Soc. Nephrol. 2010;5(2):365-370. doi: 10.2215/CJN.08091109. Epub 2010 Jan 7. Review. PubMed PMID: 20056758; PubMed Central PMCID: PMC4909119.
  96. Tondel C., Ramaswami U., Aakre K.M., et al. Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrol. Dial. Transplant. 2010;25(5):1507-1513. doi: 10.1093/ndt/gfp658. Epub 2009 Dec 27. PubMed PMID: 20038520.
  97. Seydelmann N., Wanner C., Störk S., et al. Fabry disease and the heart. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(2):195-204. Doi: 10.1016/j. beem.2014.10.003. Epub 2014 Oct 16. Review. PubMed PMID: 25987173.
  98. Weidemann F., Ertl G., Wanner C., Krämer J. The Fabry cardiomyopathy - diagnostic approach and current treatment. Curr. Pharm. Des. 2015;21(4):473- 478. Review. PubMed PMID: 25483948.
  99. Putko B.N., Wen K., Thompson R.B., et al. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev. 2015;20(2):179-191. doi: 10.1007/s10741-014-9452-9. Review. PubMed PMID: 25030479.
  100. Pieruzzi F., Pieroni M., Zachara E., et al. [Heart involvement in Anderson-Fabry disease: Italian recommendations for diagnostic, follow-up and therapeutic management]. G. Ital. Cardiol. (Rome). 2015;16(11):630-638. doi: 10.1714/2066.22434. Review. Italian. PubMed PMID: 26571477.
  101. Acharya D., Doppalapudi H., Tallaj J.A. Arrhythmias in Fabry cardiomyopathy. Card. Electrophysiol. Clin. 2015;7(2):283-291. doi: 10.1016/j.ccep.2015.03.014. Epub 2015 Apr 1. Review. PubMed PMID: 26002392.
  102. Acharya D, Robertson P., Kay G.N., et al.Arrhythmiasin Fabry cardiomyopathy. Clin. Cardiol. 2012;35(12):738-740. doi: 10.1002/clc.22047. Epub 2012 Aug
  103. Kampmann C., Wiethoff C.M., Whybra C., et al. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr. 2008;97(4):463-469. doi: 10.1111/j.1651-2227.2008.00700.x. PubMed PMID: 18363956.
  104. Biegstraaten M., van Schaik I.N., Wieling W., et al. Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC. Neurol. 2010;10:38. doi: 10.1186/1471-2377-10-38.
  105. Smid B.E., van der Tol L., Cecchi F., et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int. J. Cardiol. 2014;177(2):400-408. doi: 10.1016/j.ijcard.2014.09.001. Epub 2014 Sep 20. Review. PubMed PMID: 25442977.
  106. Franzen D., Krayenbuehl P.A., Lidove O., et al. Pulmonary involvement in Fabry disease: overview and perspectives. Eur. J. Intern. Med. 2013;24(8):707- 713. doi: 10.1016/j.ejim.2013.05.003.
  107. Svensson C.K., Feldt-Rasmussen U., Backer V. Fabry disease, respiratory symptoms,and airway limitation - a systematic review. Eur. Clin. Respir. J. 2015;2. doi: 10.3402/ecrj.v2.26721.
  108. Franzen D., Krayenbuehl P.A., Lidove O., et al. Pulmonary] involvement in Fabry disease: overview and perspectives. Eur. J. Intern. Med. 2013;24(8):707- 713. doi: 10.1016/j.ejim.2013.05.003. Epub 2013 May 30. Review. PubMed PMID: 23726861.
  109. Tuttolomondo A., Pecoraro R., Simonetta I., et al. Anderson-Fabry disease: a multiorgan disease. Curr. Pharm. Des. 2013;19(33):5974-5996.
  110. Shribman S.E., Shah A.R., Werring D.J., Cockerell O.C. Fabry disease mimicking multiple sclerosis: Lessons from two case reports. Mult. Scler. Relat. Disord. 2015;4(2):170-175. doi: 10.1016/j.msard.2015.01.001.
  111. Hoffmann B., Mayatepek E. Fabry disease-often seen, rarely diagnosed. Dtsch. Arztebl. Int. 2009;106(26):440-7. doi: 10.3238/arztebl.2009.0440.
  112. Carubbi F., Bonilauri L. Fabry disease: raising awareness of the disease among physicians. Intern. Emerg. Med. 2012;7(Suppl. 3):227-231. Doi:10.1007/ s11739-012-0821-x.
  113. Thomas A.S., Mehta A.B. Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature? Expert. Opin. Med. Diagn. 2013;7(6):589-599. doi: 10.1517/17530059.2013.846322.
  114. EUaway C. Paediatric Fabry disease. Transí. Pediatr. 2016;5(1):37-42. doi: 10.3978/j.issn.2224-4336.2015.12.02.
  115. Winchester B., Young E. Biochemical and genetic diagnosis of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 18.
  116. Matern D., Gavrilov D., Oglesbee D., et al. Newborn screening for Lysosomal storage disorders. Semin. Perinatol. 2015;39(3):206-216. Doi: 10.1053/j. semperi.2015.03.005. Epub 2015 Apr 16.
  117. Nakamura K., Hattori K., Endo F. Newborn screening for Lysosomal storage disorders. Am. J. Med. Genet. C Semin. Med. Genet. 2011;157C(1):63-71. doi: 10.1002/ajmg.c.30291.
  118. Germain D.P. Fabry disease. Orphanet. J. Rare Dis. 2010;5:30. doi: 10.1186/1750-1172-5-30.
  119. Schiffmann R., Scott L.J. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr. Suppl. 2002;91(439):48-52.
  120. Cleeland C.S. Pain assessment: the advantages of using pain scales in Lysosomal storage diseases. Acta Paediatr. Suppl. 2002;91(439):43-47.
  121. Burlina A.P., Sims K.B., Politei J.M., et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61. doi: 10.1186/14712377-11-61.
  122. Whybra C., Bähner F., Baron K. Measurement of disease severity and progression in Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 32.
  123. Arends M., Hollak C.E., Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet. J. Rare Dis. 2015;10:77. doi: 10.1186/s13023-015-0296-8.
  124. Fellgiebel A., Albrecht J., Dellani P.R., et al. Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging. Acta Paediatr. 2007;96(455):33-36.
  125. Low M., Nicholls K., Tubridy N., et al. Neurology of Fabry disease. Intern. Med. J. 2007;37(7):436-447.
  126. van der Tol L., Svarstad E., Ortiz A., et al. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Mol. Genet. Metab. 2015;114(2):242-247. doi: 10.1016/j.ymgme.2014.08.007.
  127. Smid B.E., van der Tol L., Cecchi F., et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int. J. Cardiol. 2014;177(2):400-408. doi: 10.1016/j.ijcard.2014.09.001.
  128. Najafian B., Mauer M., Hopkin R.J., Svarstad E. Renal complications of Fabry disease in children. Pediatr. Nephrol. 2013;28(5):679-687. doi: 10.1007/s00467-012-2222-9.
  129. Cybulla M., Kurschat C., West M., et al. Kidney transplantation and enzyme replacement therapy in patientswith Fabry disease. J. Nephrol. 2013;26(4):645-651. doi: 10.5301/jn.5000214. Epub 2012 Sep 19.
  130. Politei J.M. Can we use statins to prevent stroke in Fabry disease? J. Inherit. Metab. Dis. 2009;32(4):481-487. doi: 10.1007/s10545-009-1156-2.
  131. Schuller Y., Linthorst G.E., Hollak C.E., et al. Pain management strategies for neuropathic pain in Fabry disease - a systematic review. BMC. Neurol. 2016;16(1):25. doi: 10.1186/s12883-016-0549-8.
  132. Thomas A.S., Hughes D.A. Fabry disease. Pediatr. Endocrinol. Rev. 2014;12(Suppl. 1):88-101.
  133. Burlina A.P., Sims K.B., Politei J.M., et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC. Neurol. 2011;11:61. doi: 10.1186/14712377-11-61.
  134. Alegra T., Vairo F., de Souza M.V., et al. Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis. Genet. Mol. Biol. 2012;35(Suppl. 4):947-954.
  135. Schiffmann R., Moore D.F. Neurological effects of enzyme replacement therapy in Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 39.
  136. Sommer C., Uçeyler N., Duning T., et al. Pain therapy for Fabry’s disease. Internist (Berl). 2013;54(1):121-122, 124-130. doi: 10.1007/s00108-012-3204-5.
  137. Dütsch M., Hilz M.J. Neurological complications in Fabry disease. Rev. Med. Interne. 2010;31(Suppl. 2):S243-50. doi: 10.1016/S0248-8663(10)70021-7.
  138. Schiffmann R., Floeter M.K., Dambrosia J.M., et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28(6):703-710.
  139. Schiffmann R. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol. Belg. 2006;106(2):61-65.
  140. Hilz M.J., Brys M., Marthol H., et al. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology. 2004;62(7):1066-1072.
  141. Lidove O., Jaussaud R., Aractingi S. Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 24.
  142. Domínguez R.O., Michref A., Tanus E., Amartino H. Restless legs syndrome in Fabry disease: clinical feature associated to neuropathic pain is overlooked. Rev. Neurol. 2007;45(8):474-478.
  143. Toyooka K. Fabry disease. Handb. Clin. Neurol. 2013;115:629-42. doi: 10.1016/B978-0-444-52902-2.00037-0.
  144. Lidove O., Barbey F., Joly D. Treatment of Fabry disease: Successes, failures, and expectations. Nephrol. Ther. 2016. pii: S1769-7255(16)00034-1. doi: 10.1016/j.nephro.2016.02.003.
  145. Keilmann A., Hegemann S., Conti G., Hajioff D. Fabry disease and the ear. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 25.
  146. Acharya D., Doppalapudi H., Tallaj J.A. Arrhythmias in Fabry cardiomyopathy. Card. Electrophysiol. Clin. 2015;7(2):283-291. doi: 10.1016/j.ccep.2015.03.014. Epub 2015 Apr 1.
  147. Seydelmann N., Wanner C., Störk S., et al. Fabry disease and the heart. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(2):195-204. Doi: 10.1016/j. beem.2014.10.003. Epub 2014 Oct 16.
  148. Rombach S.M., Smid B.E., Linthorst G.E., et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J. Inherit. Metab. Dis. 2014;37(3):341-352. doi: 10.1007/s10545-014-9677-8.
  149. Lidove O., Barbey F., Joly D. Treatment of Fabry disease: Successes, failures, and expectations. Nephrol. Ther. 2016 Mar 8. pii: S1769-7255(16)00034-1. doi: 10.1016/j.nephro.2016.02.003.
  150. Basic-Jukic N., Kes P., Coric M., Basic-Kes V. Renal complications of Fabry disease. Curr. Pharm. Des. 2013;19(33):6046-6050.
  151. Waldek S., Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC. Nephrol. 2014;15:72. doi: 10.1186/1471-2369-15-72.
  152. Tondel C., Bostad L., Larsen K.K., et al. Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol. 2013;24(1):137-148. doi: 10.1681/ASN.2012030316. PubMed PMID: 23274955; PubMed Central PMCID: PMC3537211.
  153. Üeyler N., He L., Schönfeld D., et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J. Peripher. Nerv. Syst. 2011;16(4):304-314. doi: 10.1111/j.1529-8027.2011.00365.x.
  154. Cybulla M., Kurschat C., West M., et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J. Nephrol. 2013;26(4):645-651. doi: 10.5301/jn.5000214. Epub 2012 Sep 19. Review. PubMed PMID: 23023720.
  155. Politei J., Thurberg B.L., Wallace E., et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin. Genet. 2016;89(1):5-9. doi: 10.1111/cge.12673.
  156. Keshav S. Gastrointestinal manifestations of Fabry disease. In: Mehta A., Beck M., Sunder-Plassmann G., ed. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 28.
  157. El-Abassi R., Singhal D., England J.D. Fabry’s disease. J. Neurol. Sci. 2014;344(1-2):5-19. doi: 10.1016/j.jns.2014.06.029. Epub 2014 Jun 21.
  158. Weidemann F., Sanchez-Niño M.D., Politei J., et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet. J. Rare Dis. 2013;8:116. doi: 10.1186/1750-1172-8-116.
  159. Pieruzzi F., Salerno F., Di Giacomo A., et al. Clinical and histological findings in Fabry nephropathy. G. Ital. Nefrol. 2013;30(6). pii: gin/30.6.6.
  160. Moller A.T., Jensen T.S. Neurological manifestations in Fabry’s disease. Nat. Clin. Pract. Neurol. 200;3(2):95-106.
  161. Bugescu N., Alioto A., Segal S., et al. The neurocognitive impact of Fabry disease on pediatric patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2015; 168B(3):204-210. doi: 10.1002/ajmg.b.32297. Epub 2015 Mar 4. PubMed PMID: 25739920.
  162. Ramaswami U., Parini R., Pintos-Morell G., et al. FOS Investigators. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin. Genet. 2012;81(5):485-490. Doi: 10.1111/j. 1399-0004.2011.01671.x. Epub 2011 Apr 25. PubMed PMID: 21457233.
  163. Martin-Suárez I., Suárez-Marrero C. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease. Int. J. Clin. Pract. 2010;64(7):995. doi: 10.1111/j.1742-1241.2009.02323.x. PubMed PMID: 20584233.
  164. El Dib R.P., Nascimento P., Pastores G.M. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst. Rev. 2013;2:CD006663. doi: 10.1002/14651858.CD006663.pub3.
  165. Pisani A., Visciano B., Roux G.D., et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol. Genet. Metab. 2012;107(3):267-275. doi: 10.1016/j.ymgme.2012.08.003. Epub 2012 Aug 11.
  166. Riccio E., Capuano I., Visciano B., et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. G. Ital. Nefrol. 2013;30(5).pii:gin/30.5.5.
  167. Ghali J., Nicholls K., Denaro C., et al. Australian State Fabry Disease Treatment Centres. Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience. JIMD. Rep. 2012;3:33-43. doi: 10.1007/8904_2011_44.
  168. Deegan P.B. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J. Inherit. Metab. Dis. 2012;35(2):227-243. doi: 10.1007/s10545-011-9400-y.
  169. Milligan A., Hughes D., Goodwin S., et al. Intravenous enzyme replacement therapy: better in home or hospital?Br. J. Nurs. 2006;15(6):330-333. PubMed PMID: 16628169.
  170. Mauhin W., Lidove O., Masat E., et al. Innate and Adaptive Immune Response in Fabry Disease. JIMD. Rep. 2015;22:1-10.doi: 10.1007/8904_2014_371.
  171. Thomas A.S., Hughes D.A. Fabry disease. Pediatr. Endocrinol. Rev. 2014;12(Suppl. 1):88-101.
  172. Politei J.M., Pagano M.A. Peripheral neuropathy in Anderson-Fabry disease: its physiology, evaluation and treatment. Rev. Neurol. 2004;38(10):979-983.
  173. MacDermot J., MacDermot K.D. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur. J. Pharmacol. 2001;429(1-3): 121-125.
  174. Rozenfeld P., Neumann P.M. Treatment offabry disease: current and emerging strategies. Curr. Pharm. Biotechnol. 2011;12(6):916-922. Doi: 1389-2010/11 $58.00+.00.
  175. Ruiz de Garibay A.P., Solinís M.A., Rodríguez-Gascón A. Gene therapy for fabry disease: a review of the literature. BioDrugs. 2013;27(3):237-246. doi: 10.1007/s40259-013-0032-7.
  176. Sánchez-Fernández E.M., García Fernández J.M., Mellet C.O. Glycomimetic-based pharmacological chaperones for Lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem. Commun. (Camb). 2016;52(32):5497-5515. doi: 10.1039/c6cc01564f.
  177. Suzuki Y. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev. 2013;35(6):515-523. Doi: 10.1016/j. braindev.2012.12.002.
  178. Valayannopoulos V. Enzyme replacement therapy and substrate reduction therapy in Lysosomal storage disorders with expression. Handb. Clin. Neurol. 2013;113:1851-1857. doi: 10.1016/B978-0-444-59565-2.00055-1.
  179. Kusano E, Saito O, Akimoto T, Asano Y. Fabry disease: experience of screening dialysis patients for Fabry disease. Clin Exp Nephrol. 2014 Apr;18(2):269-273. doi: 10.1007/s10157-013-0897-2.
  180. Motabar O., Sidransky E., Goldin E., Zheng W. Fabry disease - current treatment and new drug development. Curr. Chem. Genomics. 2010;4:50-56. doi: 10.2174/1875397301004010050.
  181. Laney D.A., Bennett R.L., Clarke V., et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J. Genet. Couns. 2013;22(5):555-564. doi: 10.1007/s10897-013-9613-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies